Phase
Condition
Respiratory Syncytial Virus (Rsv) Infection
Bacterial Infections
Treatment
MeMed BV® biomarker test
Usual care
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria for main study population :
Current disease duration ≤ 7 days
Temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days
Clinical suspicion of bacterial or viral respiratory tract infection (RTI)
Exclusion Criteria for main study population:
Systemic antibiotics taken up to 48 hours prior to presentation
Outpatient steroids taken within 48 hours prior to presentation
Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis
Inflammatory disease
Congenital immune deficiency (CID)
A proven or suspected infection on the presentation with Mycobacterial, parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
Human immunodeficiency virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records)
Major trauma and/or burns in the last 7 days
Major surgery in the last 7 days
Pregnancy - Self reported or medically confirmed
Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission.
Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days
Hemodynamically unstable (require life-saving interventions such as vasopressors)
Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)
Consider unsuitable for the study by the study team
Inclusion Criteria for Subgroup:
Written informed consent must be obtained from the patient or his/her legal guardian
Current disease duration ≤ 7 days
Clinical suspicion of bacterial or viral sepsis based on 2 or more SIRS criteria OR Clinical suspicion of bacterial or viral respiratory tract infection (RTI) AND temperature ≥ 37.8°C (100°F) or tactile fever, noted at least once within the last 7 days
Patients fulfilling one or more of the following exclusion criteria from the main group are eligible for the subgroup cohort:
Systemic antibiotics taken up to 48 hours prior to presentation
Outpatient steroids taken within 48 hours prior to presentation
Suspicion and/or confirmed diagnosis of infectious gastroenteritis/colitis
Inflammatory disease (e.g., IBD, SLE, RA, other vasculitis)
Congenital immune deficiency (CID)
A proven or suspected infection on the presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
HIV, HBV, or HCV infection (self-declared or known from medical records)
Major trauma and/or burns in the last 7 days
Major surgery in the last 7 days
Pregnancy - Self reported or medically confirmed
Active malignancy of a solid tumor - Cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that is not in complete remission
Current treatment with immune-suppressive or immune-modulating therapies, at some point in the past 10 days
Hemodynamically unstable (require life-saving interventions such as vasopressors)
Patients transferred from another facility who already have a differentiated respiratory illness (known diagnosis e.g., culture positive results)
Study Design
Study Description
Connect with a study center
The University of Texas Health Science Center at Houston
Houston, Texas 77030
United StatesSite Not Available
The University of Texas Health Science Center at Houston
Houston 4699066, Texas 4736286 77030
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.